Holen Sie sich die Stockscreener-App
0.5228
0.02%
-0.000100
Schlusskurs vom Vortag:
$0.5229
Offen:
$0.5299
24-Stunden-Volumen:
100.57K
Relative Volume:
0.03
Marktkapitalisierung:
$2.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.33M
KGV:
-0.0046
EPS:
-113.7479
Netto-Cashflow:
$-9.12M
1W Leistung:
-3.15%
1M Leistung:
-25.22%
6M Leistung:
-57.50%
1J Leistung:
-88.35%
1-Tages-Spanne:
$0.5011
$0.53
1-Wochen-Bereich:
$0.48
$0.5371
52-Wochen-Spanne:
$0.4728
$6.30
Zyversa Therapeutics Inc Stock (ZVSA) Company Profile
Firmenname
Zyversa Therapeutics Inc
Sektor
Branche
Telefon
908-370-5102
Adresse
217 W. MAIN STREET, SOMERVILLE
Vergleichen Sie ZVSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZVSA
Zyversa Therapeutics Inc
|
0.5229 | 1.95M | 0 | -21.33M | -9.12M | -113.75 |
|
ONC
Beigene Ltd Adr
|
231.93 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.96 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2409 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.21 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.28 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Zyversa Therapeutics Inc Aktie (ZVSA) Neueste Nachrichten
ZyVersa Therapeutics, Inc. Provides Pipeline and Financial Update: Advances in Clinical Trials for VAR 200 and IC 100 - Nasdaq
ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress - GlobeNewswire
Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps - MSN
Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps By Stocktwits - Investing.com India
ZyVersa Unveils Groundbreaking Potential of Inflammasome - GlobeNewswire
ZyVersa Therapeutics announces developments on inflammasome inhibitors - TipRanks
ZyVersa progresses with obesity inflammation treatment - Investing.com
ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity - marketscreener.com
ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update - Stock Titan
ZyVersa Therapeutics Inc [ZVSA] is -36.75% lower this YTD. Is it still time to buy? - dbtnews.com
ZyVersa Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
How does ZVSA’s price to cash per share ratio compare in the market? - uspostnews.com
Study finds inflammation-targeting drug has Parkinson’s potential - Longevity.Technology
ZVSA: ZyVersa Therapeutics Unveils Promising Data on Parkinson's - GuruFocus
Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation - marketscreener.com
ZVSA: ZyVersa Therapeutics Unveils Promising Data on Parkinson's Treatment | ZVSA Stock News - GuruFocus
ZyVersa Therapeutics Announces Promising Data for Inflammasome ASC Inhibitor IC 100 in Parkinson's Disease Research - Nasdaq
ZyVersa Therapeutics Announces Published Data Showing - GlobeNewswire
Game-Changing Parkinson's Treatment: Nature Study Reveals Drug's Dual-Action Against Disease Progression - Stock Titan
ZyVersa progresses with novel inflammation treatment By Investing.com - Investing.com South Africa
ZyVersa progresses with novel inflammation treatment - Investing.com
ZyVersa Therapeutics CEO Issues Shareholder Letter - GlobeNewswire
ZyVersa's IC 100 Drug Targets $186B Market, Sets 2025 Clinical Timeline | ZVSA Stock News - Stock Titan
ZyVersa Therapeutics files to sell 4.21M shares of common stock by selling shareholders - MSN
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Large Drop in Short Interest - Defense World
Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday? - Yahoo Finance
10 Stocks Fall Behind Amid Market Optimism - Insider Monkey
ZyVersa CEO outlines progress in kidney disease drug development - Investing.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
ZyVersa Therapeutics Reports 2024 Financial Results and Progress - TipRanks
ZyVersa CEO outlines progress in kidney disease drug development By Investing.com - Investing.com South Africa
ZyVersa Therapeutics (ZVSA) Highlights Potential of IC 100 for O - GuruFocus
ZyVersa Therapeutics (ZVSA) Reports 2024 Financial Results and P - GuruFocus
ZyVersa Therapeutics (ZVSA) Secures $2 Million Through Securitie - GuruFocus
ZyVersa CEO issues shareholder letter on PARASOL recommendations - TipRanks
ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) - GlobeNewswire
ZyVersa Therapeutics appoints new accounting firm - Investing.com
ZyVersa Therapeutics appoints new accounting firm By Investing.com - Investing.com India
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
ZVSA stock touches 52-week low at $0.58 amid sharp annual decline By Investing.com - Investing.com South Africa
ZVSA stock touches 52-week low at $0.58 amid sharp annual decline - Investing.com Australia
Virtu Financial LLC Purchases Shares of 25,259 ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) - Defense World
ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
ZyVersa Slashes Annual Losses by 90% While Pushing Forward With Crucial Kidney Disease Drug Trial - Stock Titan
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update - Defense World
ZVSA stock touches 52-week low at $0.69 amid market challenges - Investing.com Australia
ZVSA stock touches 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa
ZyVersa Therapeutics (NASDAQ:ZVSA) vs. Keros Therapeutics (NASDAQ:KROS) Financial Analysis - Defense World
Finanzdaten der Zyversa Therapeutics Inc-Aktie (ZVSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
2.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):